Palomar Holdings, Inc. (NASDAQ:PLMR – Get Free Report) insider Jonathan Knutzen sold 281 shares of the business’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $128.04, for a total value of $35,979.24. Following the completion of the transaction, the insider directly owned 27,579 shares of the company’s stock, valued at approximately $3,531,215.16. The trade was a 1.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Jonathan Knutzen also recently made the following trade(s):
- On Thursday, January 29th, Jonathan Knutzen sold 444 shares of Palomar stock. The shares were sold at an average price of $122.04, for a total value of $54,185.76.
- On Thursday, January 29th, Jonathan Knutzen sold 444 shares of Palomar stock. The shares were sold at an average price of $122.04, for a total value of $54,185.76.
- On Saturday, January 31st, Jonathan Knutzen sold 290 shares of Palomar stock. The stock was sold at an average price of $121.74, for a total transaction of $35,304.60.
- On Wednesday, January 28th, Jonathan Knutzen sold 1,535 shares of Palomar stock. The shares were sold at an average price of $119.88, for a total transaction of $184,015.80.
Palomar Stock Down 2.3%
Shares of Palomar stock traded down $2.81 on Friday, reaching $120.61. The stock had a trading volume of 332,759 shares, compared to its average volume of 275,399. The stock has a market capitalization of $3.20 billion, a P/E ratio of 16.80 and a beta of 0.44. The company has a 50 day moving average price of $129.40 and a 200 day moving average price of $123.10. Palomar Holdings, Inc. has a 1 year low of $107.75 and a 1 year high of $175.85.
Wall Street Analysts Forecast Growth
Several research analysts recently issued reports on the company. Keefe, Bruyette & Woods upped their target price on Palomar from $170.00 to $171.00 and gave the company an “outperform” rating in a research report on Tuesday, January 6th. Weiss Ratings upgraded Palomar from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, January 14th. JPMorgan Chase & Co. upped their price objective on shares of Palomar from $145.00 to $155.00 and gave the company an “overweight” rating in a report on Wednesday, January 7th. Wall Street Zen lowered shares of Palomar from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, Evercore assumed coverage on shares of Palomar in a research report on Monday, February 9th. They set an “outperform” rating and a $150.00 target price on the stock. Seven investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $162.17.
Check Out Our Latest Stock Report on Palomar
Institutional Trading of Palomar
Several institutional investors and hedge funds have recently bought and sold shares of the business. Salomon & Ludwin LLC purchased a new stake in shares of Palomar during the 3rd quarter worth about $25,000. Richardson Financial Services Inc. increased its stake in shares of Palomar by 210.0% in the 3rd quarter. Richardson Financial Services Inc. now owns 217 shares of the company’s stock valued at $25,000 after purchasing an additional 147 shares in the last quarter. Allworth Financial LP boosted its position in Palomar by 1,970.0% during the second quarter. Allworth Financial LP now owns 207 shares of the company’s stock worth $32,000 after purchasing an additional 197 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in Palomar during the fourth quarter worth approximately $32,000. Finally, Kestra Advisory Services LLC acquired a new stake in Palomar in the fourth quarter valued at approximately $33,000. 90.25% of the stock is currently owned by institutional investors and hedge funds.
Palomar Company Profile
Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.
In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.
Recommended Stories
- Five stocks we like better than Palomar
- Free: The Crypto Summit That Could Change Your Life
- From Quiet Compounder to 2026 Breakout? BSEM
- Silver $309?
- Gilder: Don’t Buy AI Stocks, Do This Instead
- America’s 1776 happening again
Receive News & Ratings for Palomar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palomar and related companies with MarketBeat.com's FREE daily email newsletter.
